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Abstract
Background: During the last part of the 1990s the chance of surviving breast cancer increased.
Changes in survival functions reflect a mixture of effects. Both, the introduction of adjuvant
treatments and early screening with mammography played a role in the decline in mortality.
Evaluating the contribution of these interventions using mathematical models requires survival
functions before and after their introduction. Furthermore, required survival functions may be
different by age groups and are related to disease stage at diagnosis. Sometimes detailed
information is not available, as was the case for the region of Catalonia (Spain). Then one may
derive the functions using information from other geographical areas. This work presents the
methodology used to estimate age- and stage-specific Catalan breast cancer survival functions from
scarce Catalan survival data by adapting the age- and stage-specific US functions.
Methods: Cubic splines were used to smooth data and obtain continuous hazard rate functions.
After, we fitted a Poisson model to derive hazard ratios. The model included time as a covariate.
Then the hazard ratios were applied to US survival functions detailed by age and stage to obtain
Catalan estimations.
Results: We started estimating the hazard ratios for Catalonia versus the USA before and after
the introduction of screening. The hazard ratios were then multiplied by the age- and stage-specific
breast cancer hazard rates from the USA to obtain the Catalan hazard rates. We also compared
breast cancer survival in Catalonia and the USA in two time periods, before cancer control
interventions (USA 1975–79, Catalonia 1980–89) and after (USA and Catalonia 1990–2001).
Survival in Catalonia in the 1980–89 period was worse than in the USA during 1975–79, but the
differences disappeared in 1990–2001.
Conclusion: Our results suggest that access to better treatments and quality of care contributed
to large improvements in survival in Catalonia. On the other hand, we obtained detailed breast
cancer survival functions that will be used for modeling the effect of screening and adjuvant
treatments in Catalonia.
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Mortality from breast cancer has been decreasing in the
majority of industrialized countries since the beginning of
the 1990s. Extended use of mammography screening and
improvements in adjuvant therapies have been indicated
as the causes of this decline. Adjuvant therapies are drugs,
usually chemotherapy or hormonotherapy, used as addi-
tional treatments for patients with cancers that are
thought to have spread beyond their original sites.
On one hand, screening with mammography may reduce
breast cancer mortality, because more tumors are detected
at earlier stages where survival time is longer. On the other
hand, concurrently with mammography use, the intro-
duction of adjuvant therapies also may have increased the
survival time at all stages of the disease and modified the
survival functions.
Based on a collaborative effort, seven research groups
modeled the US breast cancer mortality trends from 1975
to 2000. The Cancer Intervention and Surveillance Mode-
ling Network (CISNET) is a consortium of the US
National Cancer Institute that sponsored and oversaw this
initiative [1]. All groups shared the same model inputs:
incidence, survival after breast cancer diagnosis and mor-
tality by other causes of death, over time. The goal of the
modeling process was to determine the contribution of
screening mammography and adjuvant treatments on the
reduction in breast cancer mortality [2]. One of the CIS-
NET groups, lead by Marvin Zelen and Sandra Lee at the
Dana-Farber Cancer Institute in Boston [3], developed a
stochastic model that requires specific breast cancer sur-
vival probability density functions (pdf s) by age and dis-
ease stage at diagnosis.
Catalonia is an autonomous region of Spain with author-
ity over health-care planning, administration, and provi-
sion since 1985. It has approximately 7.2 million
inhabitants, one sixth of the Spanish population. The Cat-
alan Health Department has implemented an independ-
ent information system and preventive programs in the
region. Population breast cancer screening programs were
initiated in the early 1990s [4]. All this facilitates the col-
lection of almost all the required inputs to use the Lee and
Zelen's model to study the impact of mammography and
adjuvant treatments in Catalonia. But Catalan survival
information is not reliable enough to directly derive the
survival functions by age and disease stage at diagnosis.
While stage-specific Catalan survival functions are robust,
when stratifying by age and stage the number of women
at risk over time decreases and the survival estimates are
unstable (see Additional file 1). Since younger women are
affected by more agressive tumors, it is important to esti-
mate age- and stage-specific survival functions.
This work presents the methodology used to estimate age-
and stage-specific Catalan breast cancer survival functions
from scarce Catalan survival data by adapting the age- and
stage-specific US functions. In addition, we compared
breast cancer survival in Catalonia and the USA in two
time periods, before and after the introduction of screen-
ing mammography.
Methods
This section is structured in four parts: a) The obtention of
the US breast cancer hazard rate functions, by stage and
also by age and stage; b) The description of the existent
and inferred Catalan survival data; c) The estimation of
the hazard ratios (HR) or relative hazards that compare
Catalonia versus the US, which sometimes are time-
dependent; and d) The estimation of age- and stage-spe-
cific breast cancer survival functions for Catalonia using
the US functions and the estimated HR.
US survival data
Background survival data
To understand how early screening and adjuvant thera-
pies contributed to the reduction of the breast cancer mor-
tality it is necessary to consider breast cancer survival prior
to these two interventions. During the period of 1975–79,
the two factors were absent in the USA. Thus, background
data and functions refer to these years.
Survival information following cancer diagnosis was
retrieved from the National Cancer Institute's Surveillance
Epidemiology and End Results (SEER) Program [5]. SEER
currently collects and publishes cancer incidence and sur-
vival data from population-based cancer registries cover-
ing approximately 26% of the US population.
For the period 1975–79, women diagnosed with breast
cancer were classified using the SEER historical summary
of disease stage at diagnosis (localized, regional, and dis-
tant). Localized is defined as disease confined entirely to
the organ of origin, regional is disease that has extended
beyond the limits of the organ of origin into surrounding
organs or tissue and/or regional lymph nodes, and distant
is disease with metastasis. This classification was used in
the comparison of survival in the USA and Catalonia.
From the historical summary stage information and addi-
tional data on the extent of disease, the CISNET inferred
breast cancer survival functions for the US population in
5 age groups (30–39, 40–49, 50–59, 60–69 and 70–84
years) and for 5 disease stages at diagnosis (American
Joint Committee on Cancer (AJCC) staging system: I, II-
node negative (II-), II-node positive (II+), III, IV) [6].
These 25 age- and stage-specific functions will be used to
obtain the detailed Catalan survival functions.Page 2 of 14
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Estimates of the US breast cancer specific survival func-
tions (hazard, density and cumulative survival) for the
period 1990–2001 were obtained using data output from
the SEER*Stat Survival software developed at the National
Cancer Institute [5]. The AJCC disease stage information is
provided in detail for this period: I, II, III, IV, and whether
regional nodes are affected or not. Data selection was
done using the default parameters and the Display Stand-
ard Life by Cause-Specific Survival option. Women aged 30–
84 years and with a diagnosis of breast cancer were
grouped in stages I, II-, II+, III and IV.
Hazard functions
The previously mentioned SEER and CISNET data sources
record cases with 25 years of follow-up after diagnosis for
women diagnosed during the background period, and
cases with 16 years of follow-up for women diagnosed
during the recent period. The information provided was
the number of women alive at the beginning of the inter-
val (Nt) and the number of breast cancer deaths (Dt) and
women lost to follow-up (or withdrawals, Wt) in time
intervals of 1 year [t, t + 1). Then the conditional hazard
rates ( ) by age and stage were estimated as the number of
breast cancer deaths divided by person-years at risk  = Nt
- 0.5(Dt + Wt):
The hazard rates estimated using expression (1) draw a
step function with fluctuations. We smoothed these (u)
and obtained continuous hazard rate functions using a
restricted cubic spline model (natural splines) [7]. First,
we used the function rc_spline from the STATA software
to create a series of covariates that are functions of the
independent variable time from diagnosis and predefined
knots [8-10]. These covariates take the form of piecewise
cubic polynomials between adjacent knots. Then, we run
a weighted linear regression model with dependent varia-
ble (u) estimated in (1) and the specified covariates. We
used knots at the 1.5, 2.5, 4.5, 8.5, 14.5 and 20.5 time
points for period 1975–79, and at 1.5, 2.5, 4,5 and 8.5 for
period 1990–2001. We used  as frequency weights to
account for the precision of (u).
We assumed that the number of breast cancer deaths in a
specific time interval [t, t + 1) follows a Poisson distribu-
tion with parameter (t), being (t) the smoothed
hazard rate in the midpoint of the interval. Therefore,
(t) is the expected number of deaths, Et, in the time
interval [t, t + 1). To estimate the variance and point-wise
95% confidence intervals of the US hazard rates we used
a bootstrap approach based on resampling the Pearson
residuals , being Ot the observed number of
breast cancer deaths in each time interval (see Appendix
for further details).
We derived three groups of US hazard functions:
1. For period 1975–79, 3 stage-specific functions,
using the historical stage classification (localized,
regional, and distant).
2. For period 1990–2001, 5 stage-specific functions
using the AJCC staging classification (I, II-, II+, III, IV).
3. For period 1975–79, 25 age- and stage-specific func-
tions using age groups (30–39, 40–49, 50–59, 60–69,
70–84 years) and the AJCC staging classification (I, II-
, II+, III, IV).
Catalan survival data
Background and recent survival data
Catalan breast cancer survival data is not available at the
population level. There are two population based cancer
registries that cover an area of 20% of the Catalan popula-
tion. We obtained breast cancer survival data from one of
these registries, the Girona Cancer Registry (GCR), which
currently covers an area of 700 000 inhabitants and repre-
sents approximately 10% of the Catalan population.
Breast cancer data from 1975 to 2005 collected by the
GCR was considered representative of the Catalan breast
cancer data. In 1986 the female population covered by the
registry was 227 228 women, 7.45% of the Catalan female
population (3 050 749 women) [11]. The reporting sys-
tem was based on information from the area hospital
records, pathology laboratories, and death certificates
extracted from the Catalan Mortality Registry of the Cata-
lan Government's Department of Health [12]. For the
period 1980–89, the estimated exhaustivity was 96.7%,
93.2% of cases were histologically verified [11], and the
percentage of unstaged cases was around 7%. For compar-
ison, SEER provided 4% of non-classified stages for the
same period.
For background analysis we used the period 1980–89 for
two reasons. First, during this period screening and adju-
vant therapies had no impact on the Catalan population.
And second, data prior to this period was incomplete and
inaccurate. For the recent analysis, all women incident
from 1990 to 2001 were included. Ages selected for the
lˆ
′Nt
ˆ( ) [ , )l u Dt
Nt
u t t=
′
∀ ∈ + 1 (1)
lˆ
lˆ
′Nt
lˆ
′Ntlˆ lˆ
′Ntlˆ
Zt
Ot Et
Et
=
−Page 3 of 14
(page number not for citation purposes)
BMC Cancer 2009, 9:98 http://www.biomedcentral.com/1471-2407/9/98analysis were 30 to 84 years old. Additional file 1 presents
the number of women diagnosed of breast cancer by age
and stage in the GCR.
Relative survival
Relative breast cancer survival is defined as the ratio
between observed breast cancer survival and expected sur-
vival in the general population. It corrects the excess of
mortality experienced by patients diagnosed with breast
cancer. Relative survival can be interpreted as the proba-
bility of cancer survival after adjustment for competing
causes of death [13] and is a close estimate of cause-spe-
cific survival [14]. Relative survival was estimated using a
web-based application (WAERS [15]) developed by the
Catalan Institute of Oncology which uses the Hakulinen's
method to estimate the expected survival [16], the Kaplan-
Meier's method to estimate the observed survival and the
Greenwood's method [17] to estimate confidence inter-
vals.
WAERS provided the relative cumulative survival from
GCR data. Then relative breast cancer cumulative survival
data were smoothed using the same method as for US haz-
ards. We fitted a cubic spline (knots at the 1.5, 2.5, 4.5,
8.5, 10.5 and 12.5 time points) and a regression model
weighted by the number of women at risk at the begin-
ning of each interval.
Hazard ratios (HR) of breast cancer mortality, Catalonia 
versus USA
Our goal was to obtain age- and stage-specific Catalan
breast cancer survival functions. But the number of breast
cancer cases in the GCR precluded estimation of these
functions from the GCR data. Thus, we looked for a rela-
tion between the USA and the GCR (t) at the disease
stage level, the hazard ratio (HR).
Since the size of the US population covered by SEER and
the Girona province populations were very dissimilar, we
used the USA data as reference data. First, we used the
GCR relative cumulative survival and the number of all-cause
deaths to estimate the number of deaths due to breast cancer
(Dbc) in the GCR at each year interval [t, t + 1) after diag-
nosis (see first section in the Appendix for further details).
Second, we multiplied the  by the GCR person-years at
risk to estimate the expected number of breast cancer deaths
(expectedbc) in the GCR, if the hazard rates were those of
the USA (see second section in the Appendix). Third, we
fitted a Poisson regression model with dependent variable
 and with the  as an offset variable. This
corresponds to a proportional hazards model, with the
usual Cox baseline hazard λ0 replaced by the known haz-
ard function from the US data. When the proportional
hazards assumption was not fulfilled we included a func-
tion with time from diagnosis as a covariate. The log of
time (log(t)) was the function that worked best. We
included it in the models when it was statistically signifi-
cant [18].
We checked for overdispersion by fitting negative bino-
mial regression models and assessing the significance of
the extra variation parameter. The Poisson model was ade-
quate in all cases. In addition, we assessed the goodness-
of-fit of the model using the deviance. All the final models
had non-significant p-values (> 0.05) for the deviance χ2
test. Degrees of freedom were equal to the number of
observations minus 1, or minus 2 if time was included as
a covariate.
The following equations reflect the Poisson model and
the expression used to obtain the estimated HR:
Then, the stage-specific hazard ratios were obtained as:
The model was fitted for the first 14 years after breast can-
cer diagnosis, because after 14 years of follow-up the
number of breast cancer deaths approaches 0. After year
14 we assumed that the HR was constant and equal to the
year 14 estimated value.
Ninety-five percent confidence intervals (95% CI) for the
HR were obtained using the expression:
exp(log(HR) ± 1.96 Var(log(HR))1/2) (4)
When the HR was constant over time (log(HR) = β0), the
95% CI for the HR were estimated as:
exp(β0 ± 1.96 Var(β0)1/2) (5)
When the HR was time-dependent (HR(t)), the variance
of the log(HR(t)) was obtained using the expression:
Var(log(HR(t))) = Var(β0) + log(t)2 Var(β1) + 2 log(t) 
Cov(β0, β1) (6)
Then, we used expression (4) to obtain the 95% CI of the
HR.
lˆ
lˆUSA
Dt
bc log expectedt
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log E D log t log expectedt
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mography (background), we used the 1975–1979 US haz-
ard rates and the 1980–1989 GCR person-years at risk to
estimate the GCR breast cancer deaths (expectedbc). We
performed this analysis by historical stage of disease
(localized, regional, distant). For the recent period, we
used the 1990–2001 data from the GCR and the 1975–79
data for the USA, using the AJCC five disease stages at
diagnosis (I, II-, II+, III, IV).
The following scenarios provided the periods chosen for
the comparisons:
• C1: Catalonia 1980–89 vs the USA 1975–79
• C2: Catalonia 1990–2001 vs the USA 1975–79
• C3: Catalonia 1990–2001 vs the USA 1990–2001
Comparisons C1 and C2 provide the HR needed to per-
form estimations of the Catalan breast cancer age-and
stage-specific λ(t) functions for background and for recent
time periods by using  (t) in 1975–79.
Additionally, from the HR obtained in C1 and C3, we can
assess the differences in breast cancer survival between the
USA and Catalonia, in the recent past, before the dissem-
ination of screening with mammography.
Estimation of age and stage-specific Catalan survival 
functions: λ, cumulative survival, and pdfs
We used the age- and stage-specific USA  functions in
the period 1975–79 and the HR by stage from C1 and C2
to estimate the age- and stage-specific Catalan  func-
tions for the periods 1980–89 and 1990–2001, respec-
tively. We used the same HR for all age groups within
disease stages:
To obtain the AJCC (t) for Catalonia in 1980–89 we
applied the historical stage localized HR to the USA hazard
rate functions for AJCC stages I and II-. We used the his-
torical stage regional HR for AJCC stages II+ and III, and
the disseminated HR for the AJCC stage IV.
We also assessed whether the (t) functions, esti-
mated using expression (7), fit the data well by using the
goodness-of-fit deviance statistic. We obtained the devi-
ance between the estimated breast cancer deaths in the
GCR and the predicted number of deaths obtained assum-
ing a Poisson distribution with parameter (t) with
the offset term being the number of person-years at risk. In
all cases the p-values of the χ2 deviance tests were higher
than 0.01, except for C1-Disseminated, C2-I, C2-II+, and
C3-II+.
To estimate confidence bands for the variance of  we
used the delta method [19]. First, we applied the logarith-
mic transformation:
Then, assuming independence of the hazard ratios and
the USA hazard rates:
The term  was obtained from the Poisson
regression models and the term  was
obtained using the delta method as follows. The delta
method stays that if we want to approximate the variance
of G(X) where X is a random variable with mean μ and G
is differentiable, then
G(X) = G(μ) + (X - μ)G' (μ) (10)
and
Var(G(X)) = Var(X) * [G' (μ)]2 (11)
Therefore,
with  being the variance obtained by bootstrap
as described in subsection Hazard functions of the Methods
section.
Cumulative survival is related to the hazard rate through
. Thus, the cumulative survival function in
Catalonia can be estimated as:
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BMC Cancer 2009, 9:98 http://www.biomedcentral.com/1471-2407/9/98Once the cumulative survival function S(t) is estimated,
the survival  can be obtained from the relation [17]:
pdf (t) = -dS(t)/dt (14)
Software
We used the Mathematica v6.0.3 Grid Edition software
package for almost all computations [20]. STATA 10.0 was
used to smooth data, and to fit the Poisson models [21].
SEER*Stat provided USA breast cancer specific cumulative
survival for period 1990–2001 [5].
Results
USA hazard functions
Figure 1 shows the raw and smoothed US hazard rates, by
stage and time period (historical and AJCC stages for
1975–79 and AJCC stages for 1990–2001). Figure 2
presents the observed and smoothed US hazard rates, by
age groups and AJCC stages, for the 1975–79 (background)
period. The hazard rate functions in Figure 2, together
with the estimated HR, will be used to derive the hazard
rate functions in Catalonia for the background (1980–89)
and recent (1990–2001) time periods.
Data in Figure 2 displays the high variability of the
observed US hazard rates for young women at favorable
stages and justifies the need for smoothing and deriving
these functions for Catalonia.
Catalan versus the US hazard ratios
Table 1 presents the coefficients and standard errors of the
Poisson models that make it possible to estimate the HR.
When the HR are not time-dependent (β1 = 0) the esti-
mated HR are log(β0). In three situations both parameters
β0 and β1 were not statistically different from 0, meaning
that the compared (t) functions for Catalonia and the
USA were similar.
Figure 3 shows the estimated HR and their 95% confi-
dence intervals. Horizontal lines that correspond to HR =
1 refer to non statistically different  functions. HR > 1
indicate that the risk of breast cancer death in Catalonia
was higher than in the USA and HR < 1 mean the oppo-
site. It is interesting to note that in some cases the HR val-
ues cross the HR = 1 line, indicating a change in the risk
relation which needs to be interpreted by taking into
account the confidence intervals. In addition, when the 
are low, changes in the HR may not be rellevant, for exam-
ple in the early stages of disease.
pdfˆ
lˆ
lˆ
lˆ
Stage-specific US hazard rates: observed (dots) and the smoothed function (continuous line)Figure 1
Stage-specific US hazard rates: observed (dots) and the smoothed function (continuous line). The upper row 
corresponds to the hazard rates ( ) for the SEER historical stage, period 1975–79 (C1); the middle row corresponds to  
for the AJCC stages, period 1975–79 (C2); and the bottom row corresponds to  for the AJCC stages, period 1990–2001 
(C3). Dashed lines correspond to the 95% point-wise confidence intervals.
lˆ lˆ
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BMC Cancer 2009, 9:98 http://www.biomedcentral.com/1471-2407/9/98The upper row of Figure 3 compares Catalonia 1980–89
with the USA 1975–79 (C1). For the three historical
stages, the hazard rates in Catalonia were higher than in
the USA. For the regional stage, HR increased with time,
indicating an increase in mortality risk over time in Cata-
lonia in relation to the USA.
The middle row of Figure 3 compares Catalonia 1990–
2001 with the USA 1975–79 (C2). For stages I, II- and II+
the 1990–2001  were lower than the 1975–79 ,
specially during the first years after diagnosis. For tumors
with more advanced stages there were not statistically sig-
nificant differences in the risk of death. Considering the
comparisons (C1) and (C2), in Catalonia during the
1990s there was an important improvement in breast can-
cer survival.
The lower row of Figure 3 compares Catalonia and the
USA in the same time period, 1990–2001 (C3). The (t)
functions for AJCC stages I and III, in the USA and Catalo-
nia, were similar. For stages II-, II+ and IV the  and
 were similar for the first years after breast cancer
diagnosis, but there was a tendency towards an increased
risk of death in Catalonia that is statistically significant for
later years.
Figure 4 presents the cumulative survival functions for the
three comparisons C1, C2 and C3. Each graph presents a)
the observed Catalan cumulative survival obtained from
the GCR data (dots), b) the US cumulative survival, and c)
the estimated Catalan cumulative survival obtained by
multiplying the corresponding HR by the US hazard rate
functions. Figure 4 is consistent with Figure 3 and allows
lˆCAT lˆUSA
lˆ
lˆCAT
lˆUSA
Age- and stage-specific US hazard rates in 1975–79: observed (dots) and the smoothed function (continuous line)Figure 2
Age- and stage-specific US hazard rates in 1975–79: observed (dots) and the smoothed function (continuous 
line). Dashed lines correspond to the 95% point-wise confidence intervals. Disease stage classified according to the AJCC stag-
ing system.Page 7 of 14
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BMC Cancer 2009, 9:98 http://www.biomedcentral.com/1471-2407/9/98a more intuitive interpretation of differences in breast can-
cer survival in the USA and Catalonia before and after the
utilization of screening mammography (upper and bot-
tom rows). For instance, cumulative survival after 5 and
10 years from diagnosis is higher for all stages in the USA
than in Catalonia for the background period, while lines
corresponding to period 1990–2001 are very similar for
both populations (see also Table 2).
Estimated age- and stage-specific Catalan survival 
functions
Figures 5 and 6 display the estimated age- and stage-spe-
cific (t) and cumulative survival, respectively, for Cata-
lonia in the 1980–89 (thin line) and 1990–2001 (thick
line) time periods. These functions have been derived
from the  functions in 1975–79 and the correspond-
lˆ
lˆUSA
Table 1: Fitted Poisson models that compare the hazard rate functions of the USA and Catalonia (Cat).
Comparison Stage β0 β1 Cov(β0, β1)
Coef. SE Coef. SE
Cat 1980–89 vs USA 1975–79 Localized 0.5511 0.0786 - - -
Regional 0.2392 0.0938 0.1797 0.0610 -0.0048
Distant 0.2667 0.0898 - - -
Cat 1990–2001 vs USA 1975–79 I -2.9278 0.9619 1.0937 0.5068 -0.4706
II- -1.1482 0.4722 0.5589 0.2776 -0.1223
II+ -0.8711 0.2304 0.3902 0.1417 -0.0299
III - - - - -
IV -0.4499 0.1313 0.3840 0.1125 -0.0092
Cat 1990–2001 vs USA 1990–2001 I - - - - -
II- -0.5765 0.4614 0.5387 0.2703 -0.1160
II+ -0.1054 0.2240 0.2837 0.1370 -0.0279
III - - - - -
IV -0.2916 0.1300 0.3127 0.1095 -0.0087
Note: The hazard ratios are obtained using the expression . When coefficients are not reported ("--") means that they were 
not statistically significant. Catalan data refer to the Girona Cancer Registry data.
HR t e log t( ) ( )= +b b0 1
Estimated hazard ratio functions, Catalonia versus the USAFigure 3
Estimated hazard ratio functions, Catalonia versus the USA. The upper row corresponds to the  for comparison 
C1: Cat 1980–89 versus the USA 1975–79; the middle row corresponds to C2: Cat 1990–2001 versus the USA 1975–79; and 
the bottom row corresponds to  C3: Cat 1990–2001 versus the USA 1990–2001. Dashed lines correspond to the 95% point-
wise confidence intervals.
HˆRPage 8 of 14
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Cumulative survival functionsFigure 4
Cumulative survival functions. The upper row corresponds to C1: Cat 1980–89 versus the USA 1975–79; the middle row 
corresponds to C2: Cat 1990–2001 versus the USA 1975–79; and the bottom row corresponds to C3 Cat 1990–2001 versus 
the USA 1990–2001. Observed Catalan data (dots), estimated Catalan functions using the  and Catalan versus the US 
 (continuous line), and the US cumulative survival function (dashed line).
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Table 2: Estimated relative cumulative survival at five (S(5)) and ten (S (10)) years after breast cancer diagnosis in Catalonia and the 
USA.
Source Stage N5 S(5) IC(0.95) N10 S(10) IC(0.95)
Cat 1980–89 SEER Historical stage
Localized 433 0.87 0.84 – 0.91 312 0.71 0.66 – 0.77
Regional 384 0.58 0.54 – 0.62 207 0.38 0.34 – 0.42
Distant 23 0.11 0.07 – 0.18 2 - -
USA 1975–79
Localized 16198 0.9 0.90 – 0.91 12847 0.82 0.82 – 0.83
Regional 11056 0.7 0.69 – 0.70 7172 0.54 0.54 – 0.55
Distant 603 0.2 0.18 – 0.22 219 0.11 0.10 – 0.12
Cat 1990–2001 AJCC stage
I 389 0.99 0.96 – 1.01 171 0.98 0.94 – 1.02
II- 195 0.92 0.87 – 0.97 86 0.82 0.75 – 0.90
II+ 309 0.84 0.80 – 0.89 138 0.67 0.62 – 0.73
III 103 0.58 0.50 – 0.66 41 0.44 0.36 – 0.54
IV 36 0.29 0.21 – 0.40 10 0.1 0.05 – 0.19
USA 1990–2001
I 103291 0.98 0.97 – 0.98 38284 0.94 0.94 – 0.95
II- 27528 0.92 0.92 – 0.92 10046 0.86 0.85 – 0.86
II+ 50159 0.86 0.86 – 0.86 15529 0.75 0.74 – 0.75
III 10086 0.61 0.61 – 0.62 2833 0.48 0.47 – 0.49
IV 2654 0.24 0.23 – 0.24 418 0.12 0.11 – 0.13
Note: N5 and N10 correspond to the number of women at risk at the beginning of the interval in the Girona Cancer Registry (GCR) for Catalonia 
and in the Surveillance Epidemiology and End Results (SEER) for the USA. The 95% confidence intervals were obtained using Greenwood's formula.
BMC Cancer 2009, 9:98 http://www.biomedcentral.com/1471-2407/9/98ing estimated HR. Although Figure 5 shows some overlap
between the 95% confidence intervals for the 1980–89
and the 1990–2001 hazards, the estimated functions
reflect important improvements in breast cancer survival
in Catalonia for all age groups and stages of disease.
Discussion
Our study achieves two goals. We have obtained age- and
stage-specific breast cancer survival functions for Catalo-
nia for two time periods, 1980–89 and 1990–2001. These
functions can be used 1) to assess changes over time in
survival after breast cancer diagnosis, and 2) to generate
breast cancer pdf s that are needed to model the impact of
early detection and adjuvant treatments in the reduction
of breast cancer mortality in Catalonia.
The results of this study show that breast cancer survival
in Catalonia during the 1980s was worse than in the USA
during the second half of the 1970s. But, during the 1990s
breast cancer survival in Catalonia experienced great
improvements and ended up being comparable to US sur-
vival for most disease stages.
Previous studies compared trends in breast cancer inci-
dence, mortality, and survival in 10 European countries
between 1983 and 1994 [22]. Spain and Italy started with
the lowest incidence and mortality rates which increased
markedly up to the mid 1990s, probably due to changes
in lifestyle and diet over time [23]. Despite low mortality,
the Spanish relative breast cancer survival in 1984 was
among the worst ones according to the EUROCARE study
[22]. Fortunately, the increasing trends in breast cancer
incidence and mortality (with a maximum around mid
1990s) were accompanied by the steepest increase in rela-
tive survival from 1984 to 1994, of all European countries
studied, (8% per year) [22]. Whereas breast cancer impact
on mortality increased, relative survival improved, proba-
bly due to the rapid dissemination of scientific and medi-
cal advances.
Estimated age- (years) and stage-specific Catalan hazard rate functionsFigure 5
Estimated age- (years) and stage-specific Catalan hazard rate functions. Thin line is for the period 1980–89 and 
thick line for 1990–2001. Dashed lines correspond to the 95% point-wise confidence intervals for the period 1980–89.Page 10 of 14
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BMC Cancer 2009, 9:98 http://www.biomedcentral.com/1471-2407/9/98From mid 1990s to the present, breast cancer mortality in
Catalonia shows a decreasing trend [24]. The introduction
of early screening and adjuvant treatments may have
played an important role, as in most of the western coun-
tries [25]. Both cancer control interventions seem to have
contributed similarly to the reduction in breast cancer
mortality in the USA [2]. In Catalonia, the contribution of
each still remains to be evaluated and the results of this
study will be used as inputs to the Lee and Zelen model
[3]. In this work we have observed that breast cancer sur-
vival improved from the 1980s to the 1990s within dis-
ease stages. Although earlier time of diagnosis for
mammography detected cases (lead time bias) may play a
role in the estimated survival distributions for the 1990s,
the improvement within disease stages may be related to
the introduction of better treatments, too.
When comparing breast cancer survival in different popu-
lations it is necessary to take into account that differences
in overall mortality and life expectancy influence the
cause-specific survival in these populations [13,26,27].
Relative survival and cancer-specific survival provide sim-
ilar results [14,16]. In relative survival, the total mortality
hazard is assumed to consist of the general population
mortality hazard and of an excess hazard which is attrib-
utable to cancer. In the cause-specific survival, on the
other hand, the cause-specific hazard is estimated using
the cause of death information only. The cause-specific
survival rate is calculated by censoring the survival time
related to a non-cancer death. The relative survival analy-
sis is often preferred over the cause-specific survival since
the cause of death information in the cancer registries may
be unreliable or unavailable. In this study, we have
worked with breast cancer relative survival which was
Estimated age- (years) and stage-specific Catalan cumulative survivalFigure 6
Estimated age- (years) and stage-specific Catalan cumulative survival. Thin line is for the period 1980–89 and thick 
line for 1990–2001.
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
3039 I
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
3039 II
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
3039 II
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
3039 III
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
3039 IV
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
4049 I
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
4049 II
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
4049 II
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
4049 III
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
4049 IV
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
5059 I
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
5059 II
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
5059 II
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
5059 III
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
5059 IV
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
6069 I
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
6069 II
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
6069 II
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
6069 III
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
6069 IV
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
7084 I
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
7084 II
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
7084 II
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
7084 III
0 5 10 15 20
0.2
0.4
0.6
0.8
1.0
7084 IV
years after diagnosis
StPage 11 of 14
(page number not for citation purposes)
BMC Cancer 2009, 9:98 http://www.biomedcentral.com/1471-2407/9/98obtained considering the life tables of the Catalan popu-
lation [15].
Since survival data in Catalonia was not available at the
population level and estimations of survival functions by
age groups and disease stages would have been inaccurate
and not reliable, we decided to customize the US survival
functions. The limitations of our original data led us to
undertake this study. Our assumption was that the Cata-
lan functions had age and stage patterns similar to the US
functions, but that levels of risk of breast cancer mortality
were the Catalan observed levels. As the number of breast
cancer cases in the GCR was small compared to the US
SEER cases, instead of using the Cox regression model to
compare both geographical areas, we used a Poisson
regression model that handled the US as the reference
group [28]. The Poisson regression model also made it
possible to deal with time varying hazard ratios. We
assessed the proportionality of hazards assumption and,
when necessary, we included log(time) as a covariate.
Another limitation intrinsic to the type of data that we
used is the noise and fluctuation of hazard rates. To deal
with this problem we smoothed the data and weighted it
by the number of person-years at risk in each time inter-
val. Figures 1 and 2 show that the adjusted hazard rate
functions capture the main trends of the raw data. There
are several examples in the literature that combine fitting
a spline function to the hazards and obtaining a HR as a
function of time or log(time) [29,30].
We assessed the calibration of the Catalan estimated func-
tions using the goodness-of-fit deviance statistic. The test
did not reject the null hypothesis in all but four of the
cases. The discrepancies can be attributed to the instability
of both Dbc and person-years at risk in the GCR. In general,
Figure 4 shows that the observed and predicted values of
the Catalan cumulative survival functions are very similar.
Therefore, the methods used seem to provide a robust esti-
mate of the breast cancer survival functions in Catalonia.
Conclusion
In summary, we have combined limited breast cancer sur-
vival data from Catalonia (Spain) with more robust data
from a bigger population, the USA, to obtain robust sur-
vival functions for Catalonia. Our methodology has used
standard statistical approaches that can be performed
using available software. The results of our study are use-
ful for public health and clinical purposes since they pro-
vide information on the progress against breast cancer in
Catalonia. In addition, our results provide a comparison
of Catalonia and the USA in terms of the prognosis of
women diagnosed with breast cancer. Finally we have
generated survival probability density functions for Cata-
lonia that will be used in the modeling of the impact of
screening mammography and adjuvant treatments.
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Appendix
Estimation of the confidence intervals for the US hazard 
rates
To obtain the variance and confidence intervals of the
smoothed US hazard rates, we proceed as follows:
1. We assumed that the number of breast cancer
deaths in a specific time interval [t, t + 1) follows a
Poisson distribution with mean equal to the
smoothed hazard rate in the midpoint of the interval,
(t), times the observed number of woman-years in
the interval, . Then E(t) = (t) is the expected
number of deaths in each time interval.
2. For each t, t = 1,..., T, we calculated the Pearson
residuals , being Ot the observed number
of breast cancer deaths.
3. We repeated 1,000 times:
(a) We took a random sample with replacement of
the residuals, , t = 1,..., T, and used these values
to create a random sample of count data generated
under the model using the expression
.
(b) We refited the smoothing spline model using
 and the observed woman-years, to create a
resampled hazard rate function, (t), generated
under the model.
4. From the 1,000 replicated hazard rate functions we
estimated the variance. The 95% confidence interval
lˆ
′Nt ′Ntlˆ
Zt
Ot Et
Et
=
−
Zt
b
O max E Z Et
b
t t
b
t= +( , )0
Ot
b
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BMC Cancer 2009, 9:98 http://www.biomedcentral.com/1471-2407/9/98limits were obtained using the percentiles 2.5 and 97.5
of the bootstrapped hazard rates.
Estimation of the number of breast cancer deaths in the 
GCR
To estimate the number of breast cancer deaths at each time
interval after breast cancer diagnosis, ( ), we used data
from the GCR and also the relative breast cancer survival
data obtained using the WAERS web application [15].
Data available from the GCR were the number of women at
risk at the beginning of each time interval (Nt), the number
of all-cause deaths ( ) and the number of women lost to
follow-up (Wt). The relative breast cancer cumulative sur-
vival (Sbc(t)) provided by the WAERS application made it
possible to derive the conditional probability of dying from
breast cancer, ( ), at each interval [t, t + 1):
Then, solving the following equation for each interval [t, t
+ 1):
We estimated the number of breast cancer deaths ( )
as:
Estimation of the woman-years at risk in the GCR
Woman-years at risk for each time interval [t, t + 1) were
obtained using the expression Nt - 0.5 (  + Wt) (see
previous section for notation). The implied assumption is
that either deaths or losses to follow-up occur uniformly
in each time interval. In this formula it is not necessary to
distinguish if deaths were from breast cancer or other
causes. Both types of deaths contribute similarly subtract-
ing woman-years at risk.
The number of woman-years at risk in each time interval
has been used to estimate the expected number of breast can-
cer deaths (expectedbc) in the GCR, if the hazard rates were
the US rates, as described in the Methods section.
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